1.
|
Phase: Phase II, Phase I Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02507, AMC-035, CDR0000258786, NCT00052897
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 17 and over Sponsor: NCI Protocol IDs: NCI-2012-02513, GOG-0197, U10CA027469, CDR0000269709, NCT00054041
|
|
3.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: BWH-000-P-CONS01, NCI-3074, NCT00060099, 3074
|
|
4.
|
Phase: Phase II Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000347077, AECM-0309225, NCI-5850, 5850, NCT00075569
|
|
5.
|
Phase: Phase II Type: Prevention, Treatment Status: Completed Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: Stressgen SGN-00101-0005, SGN-00101-0005, NCT00038714
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 50 Sponsor: NCI Protocol IDs: NCI-2012-02623, UCI#02-55, N01CN25139, CDR0000383786, UCIRVINE-02-55, UCIRVINE-2002-2758, NCT00091130
|
|
7.
|
Phase: Phase I Type: Prevention Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HspE7-00101-0601, NCT00493545
|